CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
HPV 非依赖性宫颈腺癌中 PD-L1 表达与免疫基质特征
英文原题：PD-L1 expression and immune stromal features in HPV-independent cervical adenocarcinoma.
查看英文原题
PD-L1 expression and immune stromal features in HPV-independent cervical adenocarcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
我们的数据表明，PD-L1 在 HPV 非依赖性 CA 中表达，尤其是在透明细胞癌中，并且 PD-L1 表达是一个负向预后标志物。我们的数据支持 PD-L1 在 HPV 非依赖性 CA 中的作用及其作为免疫治疗靶点的潜力。
研究思路结论见上方概要
人乳头状瘤病毒（HPV）非依赖性宫颈腺癌（CA）通常在晚期才被诊断出来，而治疗选择有限。因此，需要有效的治疗方案。程序性细胞死亡1（PD-1）抑制剂pembrolizumab已被批准用于治疗表达PD-配体1（PD-L1）的复发或转移性宫颈鳞状细胞癌患者。然而，尚无关于HPV非依赖性CA中PD-L1表达的数据。因此，我们评估了PD-L1表达与HPV非依赖性CA患者的临床病理特征和生存之间的关联。
我们评估了44例HPV非依赖性CA患者的PD-L1、错配修复（MMR）蛋白表达及免疫基质特征。PD-L1表达定义为联合阳性评分（CPS）≥1和肿瘤比例评分（TPS）≥1%。
14例（31.8%）观察到PD-L1表达，CPS ≥1，12例（27.3%）TPS ≥1%。基于CPS或TPS的PD-L1表达与高TIL（肿瘤浸润淋巴细胞）百分比相关（CPS = P < 0.001；TPS = P < 0.001）。PD-L1 CPS ≥1的患者比PD-L1阴性患者表现出更差的无进展生存期和总生存期（分别为P = 0.004和P = 0.023）。42例显示MMR表达完整，2例显示MSH2/MSH6缺失。
展开英文摘要原文
We evaluated PD-L1, mismatch repair (MMR) protein expression and the immune stromal features of 44 patients with HPV-independent CA. PD-L1 expression was defined as a combined positive score (CPS) ≥1 and a tumour proportion score (TPS) ≥1%.
PD-L1 expression was observed in 14 cases (31.8%) with CPS ≥1 and 12 cases (27.3%) with TPS ≥1%. PD-L1 expression, based on either the CPS or the TPS, was associated with a high tumour-infiltrating lymphocyte percentage (CPS = P < 0.001; TPS = P < 0.001). Patients with a PD-L1 CPS ≥1 showed worse progression-free survival and overall survival than PD-L1-negative patients (P = 0.004 and P = 0.023, respectively). Forty-two cases demonstrated intact MMR expression and two cases demonstrated loss of MSH2/MSH6.
Our data demonstrated that PD-L1 was expressed in HPV-independent CA, especially in clear cell carcinoma, and that PD-L1 expression is a negative prognostic marker. Our data support the role of PD-L1 in HPV-independent CA and its potential as an immunotherapeutic target.
论文信息
- 作者
- Song F、Jia M、Yu S、Cao L、Sun PL、Gao H
- 单位
- Department of Pathology, The Second Hospital of Jilin University, Changchun, Jilin, China.China
- 期刊
- Histopathology2021 Nov
- 原文标识
- PubMed 34156708 · DOI 10.1111/his.14435